U.S. market Closed. Opens in 20 hours 28 minutes

TLIS | Talis Biomedical Corporation Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue412.00K3.65MN/A10.94M3.98M2.39M
Cost of Revenue41.00K8.39M2.62MN/AN/AN/A
Gross Profit371.00K-4.74M-2.62M10.94M3.98M2.39M
Operating Expenses67.19M110.40M191.82M91.18M26.70M21.43M
Selling, General & Admin28.21M40.73M42.42M13.10M6.86M5.43M
Research & Development40.69M70.83M157.59M89.02M23.81M18.39M
Other Operating Expenses-1.72M-1.16M-8.19M-10.94M-3.98MN/A
Operating Income-66.81M-115.14M-191.82M-91.18M-26.70M-21.43M
Other Expenses / Income4.81M2.13M-220.00K54.00K-775.00K93.00K
Before Tax Income-62.01M-113.01M-192.04M-91.13M-27.47M-21.34M
Income Tax ExpensesN/A-2.13M-1.58M-54.00K-42.00K93.00K
Net Income-62.01M-110.89M-190.46M-91.08M-27.43M-21.34M
Interest ExpensesN/AN/AN/AN/AN/AN/A
Basic Shares Outstanding1.82M1.78M1.51M290.00K150.00K150.42K
Diluted Shares Outstanding1.82M1.78M1.51M290.00K150.00K150.42K
EBITDA-66.05M-106.31M-191.82M-90.42M-25.97M-20.78M
EBITDA Margin-16,030.34%-2,910.98%0.00%-826.67%-653.08%-869.58%
EBIT-62.01M-113.01M-192.04M-91.13M-27.47M-21.24M
EBIT Margin-15,050.24%-3,094.52%0.00%-833.15%-690.82%-888.87%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙